OPKO Health (NASDAQ:OPK) Announces Earnings Results

OPKO Health (NASDAQ:OPK) issued its earnings results on Tuesday. The biotechnology company reported ($0.12) EPS for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.03), Briefing.com reports. The company had revenue of $173.70 million during the quarter, compared to analyst estimates of $182.99 million. OPKO Health had a negative net margin of 21.76% and a negative return on equity of 12.69%. The business’s revenue was down 26.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.02) earnings per share.

OPKO Health Trading Down 8.5 %

NASDAQ:OPK opened at $1.19 on Wednesday. The stock has a market cap of $829.42 million, a price-to-earnings ratio of -5.20 and a beta of 1.81. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.22 and a current ratio of 1.55. OPKO Health has a 1 year low of $0.85 and a 1 year high of $2.24. The business has a fifty day moving average of $1.14 and a 200-day moving average of $1.22.

Insider Activity at OPKO Health

In related news, CEO Phillip Md Et Al Frost purchased 500,000 shares of the company’s stock in a transaction on Wednesday, February 28th. The shares were bought at an average cost of $0.99 per share, for a total transaction of $495,000.00. Following the transaction, the chief executive officer now owns 208,868,225 shares of the company’s stock, valued at $206,779,542.75. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have purchased a total of 3,100,000 shares of company stock worth $2,923,000 over the last ninety days. 47.26% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on OPK shares. HC Wainwright restated a “buy” rating and set a $3.00 price objective on shares of OPKO Health in a research note on Wednesday, April 3rd. Barrington Research restated an “outperform” rating and set a $1.50 price target on shares of OPKO Health in a research report on Monday, April 1st. Piper Sandler reiterated an “overweight” rating and issued a $5.00 price objective on shares of OPKO Health in a research report on Monday, April 1st. Finally, StockNews.com cut shares of OPKO Health from a “hold” rating to a “sell” rating in a research report on Friday, March 1st.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.